Related Experiment Video

Updated: Jan 18, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.7K

Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1,

Yu Kaku1, Mizuka Fujiwara2, Keiya Uriu3

  • 1Department of Clinical Infectious Diseases, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan; Nagoya City University East Medical Center, Aichi, Japan.

The Lancet. Infectious Diseases
|January 15, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.2K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.4K

Related Experiment Videos

Last Updated: Jan 18, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.7K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.2K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.4K

Related Concept Videos

Vaccinations01:51

Vaccinations

51.3K
Overview
51.3K
Humoral Immune Responses01:36

Humoral Immune Responses

83.4K
Overview
83.4K
Cross-reactivity00:42

Cross-reactivity

32.9K
Overview
32.9K
Immunological Memory01:23

Immunological Memory

15.1K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
15.1K
Active versus Passive Immunity01:31

Active versus Passive Immunity

10.0K
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
10.0K

Articles linked to this work by shared authors, journal, and citation graph.

Novel African Rhinolophus bat ACE2 sequences reveal the determinants of Afro-Eurasian sarbecovirus entry.

Journal of virology·2026

From sites to structure to serology: a roadmap for structure-aware molecular evolution of antigenically evolving viruses.

Journal of virology·2026

Inferring context-specific site variation with evotuned protein language models.

NAR genomics and bioinformatics·2026

Humoral immunity induced by XEC monovalent vaccines against SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2.

Vaccine·2026

A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity.

Nature communications·2025

Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.

Journal of virology·2025

Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial.

The Lancet. Infectious diseases·2026

The risk of mpox false positive results in high transmission settings: evidence from a multi-site observational study in DR Congo.

The Lancet. Infectious diseases·2026

Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial.

The Lancet. Infectious diseases·2026

Is a tiered classification framework needed for sexually transmitted infections?

The Lancet. Infectious diseases·2026

Nucleic acid amplification testing and genome sequencing for WHO priority viruses in Africa: a scoping review.

The Lancet. Infectious diseases·2026

Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study.

The Lancet. Infectious diseases·2026

Large-Bore Aspiration Thrombectomy for Recurrent Iliofemoral DVT in Congenital IVC Interruption With Azygous Continuation.

JACC. Case reports·2026

Healthy bone marrow transplantation into hypertriglyceridemic rats improves cardiac reparative fibrosis post-myocardial infarction.

Cardiovascular research·2026

Exploring antibody-antigen binding affinity using degree-based topological indices: a graph-theoretical approach.

Frontiers in chemistry·2026

Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chimeric antigen receptor T-cell immunotherapy in an advanced disease stage: A case report.

Experimental and therapeutic medicine·2026

Soluble CTLA-4 as a context-dependent immune checkpoint: biology, biomarker potential, and therapeutic implications.

Frontiers in immunology·2026

Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A.

Blood vessels, thrombosis & hemostasis·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us